Search details
1.
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
Vaccine
; 41(23): 3518-3524, 2023 05 26.
Article
in English
| MEDLINE | ID: mdl-37142462
2.
Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis.
Drug Saf
; 46(1): 99-108, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36369456
3.
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
Lancet Respir Med
; 10(5): 435-446, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35026180
4.
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults.
Hum Vaccin Immunother
; 18(1): 1981085, 2022 12 31.
Article
in English
| MEDLINE | ID: mdl-34614379
5.
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study.
Vaccine
; 39(45): 6628-6636, 2021 10 29.
Article
in English
| MEDLINE | ID: mdl-34635373
6.
Clinical efficacy of cell culturederived and eggderived inactivated subunit influenza vaccines in healthy adults.
Clin Infect Dis
; 51(9): 997-1004, 2010 Nov 01.
Article
in English
| MEDLINE | ID: mdl-20868284
7.
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
Vaccine
; 38(44): 6930-6940, 2020 10 14.
Article
in English
| MEDLINE | ID: mdl-32883555
8.
Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.
Vaccine
; 38(16): 3227-3234, 2020 04 03.
Article
in English
| MEDLINE | ID: mdl-32169390
9.
Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10â¯years antibody persistence.
Vaccine
; 37(32): 4623-4629, 2019 07 26.
Article
in English
| MEDLINE | ID: mdl-29397225
10.
MenACWY-CRM conjugate vaccine booster dose given 4-6â¯years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults.
Vaccine
; 37(42): 6171-6179, 2019 09 30.
Article
in English
| MEDLINE | ID: mdl-31495595
11.
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Hum Vaccin Immunother
; 14(1): 45-58, 2018 01 02.
Article
in English
| MEDLINE | ID: mdl-29172945
12.
One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
J Travel Med
; 23(3)2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26994987
13.
Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.
Travel Med Infect Dis
; 13(3): 241-50, 2015.
Article
in English
| MEDLINE | ID: mdl-26005163
14.
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Hum Vaccin Immunother
; 11(2): 358-76, 2015.
Article
in English
| MEDLINE | ID: mdl-25621884
15.
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Vaccine
; 33(1): 174-81, 2015 Jan 01.
Article
in English
| MEDLINE | ID: mdl-25444803
16.
Meningitis C vaccine (North American vaccine).
Curr Opin Investig Drugs
; 3(1): 51-3, 2002 Jan.
Article
in English
| MEDLINE | ID: mdl-12054072
17.
Long-term solutions for the problem of vaccine shortages.
Expert Opin Biol Ther
; 4(6): 989-92, 2004 Jun.
Article
in English
| MEDLINE | ID: mdl-15174980
18.
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Hum Vaccin Immunother
; 10(8): 2395-407, 2014.
Article
in English
| MEDLINE | ID: mdl-25424947
19.
Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Pediatr Infect Dis J
; 33(12): e320-9, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-24978857
20.
mTOR inhibition improves immune function in the elderly.
Sci Transl Med
; 6(268): 268ra179, 2014 Dec 24.
Article
in English
| MEDLINE | ID: mdl-25540326